CAR T cell immunotherapy, which uses a patient’s own modified immune cells to find and destroy cancer cells, can produce dramatic results when treating blood cancers, such as lymphoma and leukemia, ...
In a phase 1 study, anti-CD7 chimeric antigen receptor (CAR) T cells induced complete remission in children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia (ALL), with 82% ...
How do immune cells strike a balance, unleashing rapid attacks against pathogens or cancer, while avoiding damage to healthy cells? Research into an immune kill switch holds potential for controlling ...
CAR T cell immunotherapy, which uses a patient's own modified immune cells to find and destroy cancer cells, can produce dramatic results when treating blood cancers like lymphoma and leukemia and ...
T cells are central mediators of autoimmune disease pathogenesis, yet their functional states are not defined solely by antigen recognition or canonical ...
A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results